196 related articles for article (PubMed ID: 36873155)
1. Design, synthesis, and cytotoxic evaluation of quinazoline derivatives bearing triazole-acetamides.
Pedrood K; Taayoshi F; Moazzam A; Iraji A; Yavari A; Ansari S; Sajjadi-Jazi SM; Mohajeri-Tehrani MR; Garmsiri N; Haghpanah V; Soleymanibadi M; Larijani B; Hamedifar H; Adibpour N; Mahdavi M
Heliyon; 2023 Feb; 9(2):e13528. PubMed ID: 36873155
[TBL] [Abstract][Full Text] [Related]
2. [1,2,4]Triazolo[4,3-c]quinazoline and bis([1,2,4]triazolo)[4,3-a:4',3'-c]quinazoline derived DNA intercalators: Design, synthesis, in silico ADMET profile, molecular docking and anti-proliferative evaluation studies.
El-Adl K; Ibrahim MK; Alesawy MSI; Eissa IH
Bioorg Med Chem; 2021 Jan; 30():115958. PubMed ID: 33360576
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, molecular docking and anti-proliferative evaluations of [1,2,4]triazolo[4,3-a]quinoxaline derivatives as DNA intercalators and Topoisomerase II inhibitors.
El-Adl K; El-Helby AA; Sakr H; Elwan A
Bioorg Chem; 2020 Dec; 105():104399. PubMed ID: 33113414
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, molecular docking and anticancer evaluations of 5-benzylidenethiazolidine-2,4-dione derivatives targeting VEGFR-2 enzyme.
El-Adl K; El-Helby AA; Sakr H; Eissa IH; El-Hddad SSA; M I A Shoman F
Bioorg Chem; 2020 Sep; 102():104059. PubMed ID: 32653608
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, molecular docking and in silico ADMET profile of pyrano[2,3-d]pyrimidine derivatives as antimicrobial and anticancer agents.
Abd El-Sattar NEA; El-Adl K; El-Hashash MA; Salama SA; Elhady MM
Bioorg Chem; 2021 Oct; 115():105186. PubMed ID: 34314914
[TBL] [Abstract][Full Text] [Related]
6. Annulated pyrazole derivatives as a novel class of urokinase (uPA) inhibitors: Green synthesis, anticancer activity, DNA-damage evaluation, and molecular modelling study.
Farag PS; AboulMagd AM; Hemdan MM; Hassaballah AI
Bioorg Chem; 2023 Jan; 130():106231. PubMed ID: 36335649
[TBL] [Abstract][Full Text] [Related]
7. Design, green synthesis, molecular docking and anticancer evaluations of diazepam bearing sulfonamide moieties as VEGFR-2 inhibitors.
Saleh NM; El-Gaby MSA; El-Adl K; Abd El-Sattar NEA
Bioorg Chem; 2020 Nov; 104():104350. PubMed ID: 33142416
[TBL] [Abstract][Full Text] [Related]
8. Novel halogenated arylvinyl-1,2,4 trioxanes as potent antiplasmodial as well as anticancer agents: Synthesis, bioevaluation, structure-activity relationship and in-silico studies.
Tiwari MK; Coghi P; Agrawal P; Yadav DK; Yang LJ; Congling Q; Sahal D; Wai Wong VK; Chaudhary S
Eur J Med Chem; 2021 Nov; 224():113685. PubMed ID: 34303874
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and Preclinical Evaluation of Indole Triazole Conjugates as Microtubule Targeting Agents that are Effective against MCF-7 Breast Cancer Cell Lines.
Yele V; Pindiprolu SKSS; Sana S; Ramamurty DSVNM; Madasi JRK; Vadlamani S
Anticancer Agents Med Chem; 2021; 21(8):1047-1055. PubMed ID: 32981511
[TBL] [Abstract][Full Text] [Related]
10. New tetrazolopyrrolidine-1,2,3-triazole analogues as potent anticancer agents: design, synthesis and molecular docking studies.
Gandham SK; Kudale AA; Allaka TR; Chepuri K; Jha A
Mol Divers; 2023 Nov; ():. PubMed ID: 37938509
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and Biological Evaluation of 1,2,3-Triazole Tethered Thymol-1,3,4-Oxadiazole Derivatives as Anticancer and Antimicrobial Agents.
Almalki ASA; Nazreen S; Malebari AM; Ali NM; Elhenawy AA; Alghamdi AAA; Ahmad A; Alfaifi SYM; Alsharif MA; Alam MM
Pharmaceuticals (Basel); 2021 Aug; 14(9):. PubMed ID: 34577567
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, anticancer activity and docking studies of novel quinazoline-based thiazole derivatives as EGFR kinase inhibitors.
Raghu MS; Swarup HA; Shamala T; Prathibha BS; Kumar KY; Alharethy F; Prashanth MK; Jeon BH
Heliyon; 2023 Sep; 9(9):e20300. PubMed ID: 37809937
[TBL] [Abstract][Full Text] [Related]
13. Synthesis, cytotoxic evaluation, and molecular docking studies of novel quinazoline derivatives with benzenesulfonamide and anilide tails: Dual inhibitors of EGFR/HER2.
Alkahtani HM; Abdalla AN; Obaidullah AJ; Alanazi MM; Almehizia AA; Alanazi MG; Ahmed AY; Alwassil OI; Darwish HW; Abdel-Aziz AA; El-Azab AS
Bioorg Chem; 2020 Jan; 95():103461. PubMed ID: 31838290
[TBL] [Abstract][Full Text] [Related]
14. Novel pyrazole-based COX-2 inhibitors as potential anticancer agents: Design, synthesis, cytotoxic effect against resistant cancer cells, cell cycle arrest, apoptosis induction and dual EGFR/Topo-1 inhibition.
Halim PA; Sharkawi SMZ; Labib MB
Bioorg Chem; 2023 Feb; 131():106273. PubMed ID: 36444790
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, molecular docking, anticancer evaluations, and in silico pharmacokinetic studies of novel 5-[(4-chloro/2,4-dichloro)benzylidene]thiazolidine-2,4-dione derivatives as VEGFR-2 inhibitors.
El-Adl K; El-Helby AA; Sakr H; Ayyad RR; Mahdy HA; Nasser M; Abulkhair HS; El-Hddad SSA
Arch Pharm (Weinheim); 2021 Feb; 354(2):e2000279. PubMed ID: 33073374
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and anti-proliferative activity of a novel 1,2,3-triazole tethered chalcone acetamide derivatives.
Vanaparthi S; Bantu R; Jain N; Janardhan S; Nagarapu L
Bioorg Med Chem Lett; 2020 Aug; 30(16):127304. PubMed ID: 32631524
[TBL] [Abstract][Full Text] [Related]
17. Morpholine substituted quinazoline derivatives as anticancer agents against MCF-7, A549 and SHSY-5Y cancer cell lines and mechanistic studies.
Dwivedi AR; Kumar V; Prashar V; Verma A; Kumar N; Parkash J; Kumar V
RSC Med Chem; 2022 May; 13(5):599-609. PubMed ID: 35694693
[TBL] [Abstract][Full Text] [Related]
18. Anticancer activity of newly synthesized 1,1-disubstituted cyclohexane-1-carboxamides: in vitro caspases mediated apoptosis activators in human cancer cell lines and their molecular modeling.
Abd-Allah WH; Salman A; Sabry Saad S
Drug Dev Res; 2019 Nov; 80(7):933-947. PubMed ID: 31343754
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and evaluation of novel 1,2,4-triazole derivatives as promising anticancer agents.
Emami L; Sadeghian S; Mojaddami A; Khabnadideh S; Sakhteman A; Sadeghpour H; Faghih Z; Fereidoonnezhad M; Rezaei Z
BMC Chem; 2022 Nov; 16(1):91. PubMed ID: 36369166
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, molecular docking, and anticancer evaluations of 1-benzylquinazoline-2,4(1H,3H)-dione bearing different moieties as VEGFR-2 inhibitors.
El-Adl K; El-Helby AA; Sakr H; El-Hddad SSA
Arch Pharm (Weinheim); 2020 Aug; 353(8):e2000068. PubMed ID: 32510731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
